BPC-157 vs Growth Hormone
Head-to-head comparison of BPC-157 and Growth Hormone for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Bpc 157 | Growth Hormone |
|---|---|---|
| Category | Healing & Recovery | Hormone |
| Mechanism | BPC-157 acts through multiple overlapping pathways. It promotes angiogenesis by upregulating VEGFR2 and VEGF expression, and activates nitric oxide synthesis via the Src kinase-caveolin-1 pathway and Akt-eNOS axis. | Growth hormone binds to the GH receptor (GHR), a type I cytokine receptor, activating the JAK2-STAT5 signaling pathway. |
| Evidence Rating | C — Phase I–II Clinical Trials | A — FDA Approved |
| Clinical Status | Research-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway. | FDA-approved for multiple indications. First approved in 1985 (recombinant form). |
| Safety Profile | No completed randomized controlled human clinical trials for safety assessment; Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology | Common: injection site reactions, edema, joint pain (arthralgia), carpal tunnel syndrome, muscle pain (myalgia); Metabolic: glucose intolerance, insulin resistance (dose-dependent), potential progression to type 2 diabetes |
| Route | Subcutaneous (preferred), Intramuscular, or Oral | Subcutaneous |
| Dose Range | 200–600 mcg/day SC; oral doses studied at 1–6 mg in clinical trials | Adults: 0.15–0.3 mg/day SC (GH deficiency); Pediatric: 0.025–0.05 mg/kg/day SC |
| Frequency | Once daily | Once daily (typically evening) |
| Molecular Weight | ~1419.5 g/mol | ~22,124 g/mol |
| Half-Life | ~15 min IV (animal data); oral activity persists 24+ hours | ~20-30 min (endogenous IV); SC injection effective duration ~12-16 hours |
Overview
BPC-157 and Growth Hormone are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
BPC-157 — Mechanism & Evidence
BPC-157 is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 g/mol) derived from a protein found in human gastric juice. It has demonstrated robust regenerative and cytoprotective effects across hundreds of animal studies spanning tendon, ligament, muscle, bone, nerve, GI tract, and blood vessel healing. However, human clinical data is extremely limited — only three pilot studies have examined BPC-157 in humans as of 2025 (knee pain n=16, interstitial cystitis n=12, IV safety n=2). The FDA classifies it as Category 2, prohibiting compounding, and WADA bans its use in sports.
Key claims: Accelerates tendon and ligament healing; Heals gut lining and treats leaky gut; Reverses NSAID-induced GI damage.
BPC-157 5mg
5mg
BPC-157 10mg
10mg
Growth Hormone — Mechanism & Evidence
Human growth hormone (hGH, somatotropin) is a 191-amino acid protein produced by the anterior pituitary gland. It is one of the most extensively studied hormones in medicine.
Key claims: Treats growth hormone deficiency in children; Treats adult growth hormone deficiency; Anti-aging effects.
Shared Research Applications
These peptides target different research areas. BPC-157 focuses on Injury Recovery, Gut Health, while Growth Hormone targets GH Deficiency Treatment, Pediatric Growth Disorders, Reference.
Safety Considerations
BPC-157: No completed randomized controlled human clinical trials for safety assessment Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.
Growth Hormone: Common: injection site reactions, edema, joint pain (arthralgia), carpal tunnel syndrome, muscle pain (myalgia) Metabolic: glucose intolerance, insulin resistance (dose-dependent), potential progression to type 2 diabetes Fluid retention: peripheral edema, especially at treatment initiation
Shop Research Peptides
BPC-157 5mg
5mg
BPC-157 10mg
10mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
Tirzepatide 10mg
10mg
KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
TB-500 vs BPC-157: Evidence, Dosing, Safety Compared
This reference compares TB-500 and BPC-157 across mechanism, dosing, evidence, safety, and pharmacokinetics, highlighting the thin comparative evidence and the need for further study.
BPC-157 News: FDA Advisers Weigh Easing Restrictions on Six Peptides
FDA advisers have reportedly supported easing restrictions on six peptides, a move that could reshape the peptide research landscape. While BPC-157 and TB-500 were not explicitly named, the decision signals growing regulatory attention. Here's what researchers and industry professionals should know.
BPC-157 News: Hydreight Updates Peptide Platform After FDA Advisory
Hydreight has issued a business update on its peptide healthcare platform following recent FDA advisory committee recommendations. The update highlights the growing regulatory attention on GLP-1 drugs like Ozempic and Wegovy, and what it means for peptide research and industry stakeholders.